Evidence map›Paper›PMID 38984578›Full record

ArticleCurrent topics in medicinal chemistry2024

The General Neurocognitive Decline in Patients with Methamphetamine Use and Transient Methamphetamine-induced Psychosis is Primarily Determined by Oxidative and AGE-RAGE Stress.

Michael Maes, Mazin Fadhil Altufaili, Amer Fadhil Alhaideri, Shatha Rouf Moustafa, Kristina Stoyanova, Mengqi Niu, Bo Zhou, Jing Li, Hussein Kadhem Al-Hakeim

Abstract read
PubMed Publisher
In one paragraph

Article in Current topics in medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Neurochemistry of Psychosis.Current topics in medicinal chemistry · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Michael MaesSichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.
Mazin Fadhil AltufailiDepartment of Chemistry, College of Science, University of Kufa, Iraq.
Amer Fadhil AlhaideriSenior Psychiatrist at the College of Medicine, University of Kerbala, Iraq.
Shatha Rouf MoustafaClinical Analysis Department, College of Pharmacy, Hawler Medical University, Erbil, Iraq.
Kristina StoyanovaDepartment of Psychiatry, Medical University of Plovdiv, Plovdiv, Bulgaria.
Mengqi NiuSichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.
Bo ZhouSichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.
Jing LiSichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.
Hussein Kadhem Al-HakeimDepartment of Chemistry, College of Science, University of Kufa, Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic Methamphetamine (MA) usage is linked to oxidative and AGE (advanced glycation end products) - RAGE (receptors for AGEs) stress, changes in magnesium, calcium, and copper, increased psychotic symptoms, and neurocognitive deficits. Nevertheless, it is still unclear whether these biological pathways mediate the latter impairments.

objectiveThis study aimed to investigate the relationships between neurocognition, the aforementioned biomarkers, and psychotic symptoms.

methodsWe recruited 67 participants, namely 40 patients diagnosed with MA-substance use and 27 healthy controls, and assessed the Brief Assessment of Cognition in Schizophrenia (BACS), symptoms of psychosis, excitation, and formal thought disorders, oxidative toxicity (computed as the sum of myeloperoxidase (MPO), oxidized high-density lipoprotein (HDL), oxidized low-DL, and malondialdehyde), antioxidant defenses (catalase, glutathione peroxidase, total antioxidant capacity, zinc, and HDL), and increased AGEs and RAGEs.

resultsWe were able to extract one validated latent vector from the Mini-Mental State Examination score and the BACS test results (including executive functions, verbal fluency, and attention), labeled general cognitive decline (G-CoDe). We found that 76.1% of the variance in the G-CoDe was explained by increased oxidative toxicity, lowered antioxidant defenses, number of psychotic episodes, and MA dose. In patients with MA use, MPO was significantly associated with the GCoDe.

conclusionThe use of MA induced mild cognitive impairments through MA-induced activation of detrimental outcome pathways, including oxidative and AGE-RAGE stress, and suppression of protective antioxidant pathways. Increased MPO, oxidative, and AGE-RAGE stress are new drug targets to prevent neurocognitive deficits and psychosis due to MA use.

Indexed as

Glycation End Products, AdvancedMethamphetamineOxidative StressAdultCognitive DysfunctionFemaleHumansMaleMiddle AgedPsychoses, Substance-InducedPsychotic DisordersReceptor for Advanced Glycation End ProductsYoung AdultGlycation End Products, AdvancedMethamphetamineReceptor for Advanced Glycation End ProductsAntioxidantsBiomarkersNeurocognition.Oxidative and nitrosative stressPathophysiologySchizophrenia

Identifiers

PMID38984578

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.